Pune-headquartered Serum Institute of India (SII), the world’s largest vaccine maker by quantity, has been in the spotlight, having committed itself to supplying 3.2 billion doses of the Covid-19 vaccine. This is more than double the company’s FY20 production of 1.5 billion doses. Apart from global agencies like Geneva-based Gavi (earlier called Global Alliance for Vaccines and Immunisation) procuring from SII, the Indian vaccination programme too will bank on it. In an e-mail interview with Sohini Das, Adar Poonawalla, chief executive officer, Serum Institute of India, says the firm is not raising additional capital through private equity. SII is researching two new coronavirus vaccines on its own, he adds.
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.
Already a premium subscriber? LOGIN NOW
SUBSCRIBE TO INSIGHTS
What you get on Business Standard Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- 26 years of website archives.
- Preferential invites to Business Standard events.